Rokos H, Rokos K, Frisius H, Kirstaedter H J
Clin Chim Acta. 1980 Aug 4;105(2):275-86. doi: 10.1016/0009-8981(80)90470-2.
Urinary pteridine concentrations in healthy control subjects and patients with cancer and non-malignant diseases were determined by HPLC and TLC after partial purification by ion exchange and Sephadex chromatography. Elevated concentrations of neopterin were found in 70% of the 50 cancer patients investigated. In patients with non-Hodgkin's lymphoma (seven cases) or with liver metastases (12 cases) neopterin concentrations were significantly higher than in control subjects (p < 0.01). Biopterin was less frequently increased (22%). Xanthopterin was generally raised when neopterin and/or biopterin excretion was high. Neopterin/biopterin ratios were higher in some patients with cancer or with severe renal insufficiency than in controls. These findings suggest that alterations in pteridine metabolism are common in malignant disease. The pathogenic, diagnostic and therapeutic significance of these changes remains to be established.
通过离子交换和葡聚糖凝胶色谱法进行部分纯化后，采用高效液相色谱法（HPLC）和薄层色谱法（TLC）测定了健康对照受试者、癌症患者和非恶性疾病患者的尿蝶啶浓度。在所研究的50例癌症患者中，70%发现新蝶呤浓度升高。在非霍奇金淋巴瘤患者（7例）或有肝转移的患者（12例）中，新蝶呤浓度显著高于对照受试者（p < 0.01）。生物蝶呤升高的情况较少见（22%）。当新蝶呤和/或生物蝶呤排泄量高时，黄蝶呤通常会升高。一些癌症患者或严重肾功能不全患者的新蝶呤/生物蝶呤比值高于对照组。这些发现表明，蝶啶代谢改变在恶性疾病中很常见。这些变化的致病、诊断和治疗意义仍有待确定。
